Cargando…

Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

OBJECTIVES: The study aimed to assess the usefulness of the determination of cytokines: IL-8, VEGF and its soluble receptors: VEGF-R1, VEGF-R2 in patients with endometrial cancer (EC). MATERIAL/METHODS: The study group consisted of 118 patients with EC subjected to surgical treatment. Before the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotowicz, Beata, Fuksiewicz, Malgorzata, Jonska-Gmyrek, Joanna, Berezowska, Alicja, Radziszewski, Jakub, Bidzinski, Mariusz, Kowalska, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633267/
https://www.ncbi.nlm.nih.gov/pubmed/28991928
http://dx.doi.org/10.1371/journal.pone.0184576
_version_ 1783269858825207808
author Kotowicz, Beata
Fuksiewicz, Malgorzata
Jonska-Gmyrek, Joanna
Berezowska, Alicja
Radziszewski, Jakub
Bidzinski, Mariusz
Kowalska, Maria
author_facet Kotowicz, Beata
Fuksiewicz, Malgorzata
Jonska-Gmyrek, Joanna
Berezowska, Alicja
Radziszewski, Jakub
Bidzinski, Mariusz
Kowalska, Maria
author_sort Kotowicz, Beata
collection PubMed
description OBJECTIVES: The study aimed to assess the usefulness of the determination of cytokines: IL-8, VEGF and its soluble receptors: VEGF-R1, VEGF-R2 in patients with endometrial cancer (EC). MATERIAL/METHODS: The study group consisted of 118 patients with EC subjected to surgical treatment. Before the treatment we determined the serum levels of cytokines IL-8, and VEGF as well as VEGFR1 and VEGFR2 receptors. For comparison, the concentration of CA 125 was also measured. VEGFR1 and CA 125 were determined in the COBAS e601 system using Roche Diagnostics kits, while IL-8, VEGF and VEGFR2 were measured by ELISA assay using R&D Systems kits. RESULTS: The concentrations of IL-8, VEGF, VEGFR1 and CA 125 allowed to distinguish patients for the control group. The highest diagnostic sensitivity has been shown for the concentrations of VEGF (AUC = 0.904) and IL-8 (AUC = 0.818). Among all studied parameters only CA125 concentrations increased with the clinical stage; being significantly higher in patients in FIGO III-IV, than FIGO I-IB. In patients at the FIGO stage I-IB, complementary determinations of CA 125 and VEGF resulted in the largest increase of diagnostic sensitivity. Patients with metastases to the para-aortic lymph nodes had significantly higher levels of VEGF compared to subjects without such lesions. The concentrations of IL-8 were an independent prognostic factor in the assessment of overall survival in patients with type I endometrial cancer, while the concentrations of VEGFR2 in those with type II. CONCLUSIONS: In patients with endometrial cancer, the clinical usefulness of IL-8 and VEGFR2 measurements as the potential prognostic factors has been demonstrated. In type I, the concentrations of IL-8 determined before treatment can be helpful in predicting overall survival. In patients qualified to type II EC, the concentrations of VEGFR2 have the value of an independent prognostic factor for overall survival, this requires research on larger groups of patients. The increased levels of VEGF may be useful in the preoperative assessment of the status of para-aortic lymph nodes.
format Online
Article
Text
id pubmed-5633267
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56332672017-10-30 Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients Kotowicz, Beata Fuksiewicz, Malgorzata Jonska-Gmyrek, Joanna Berezowska, Alicja Radziszewski, Jakub Bidzinski, Mariusz Kowalska, Maria PLoS One Research Article OBJECTIVES: The study aimed to assess the usefulness of the determination of cytokines: IL-8, VEGF and its soluble receptors: VEGF-R1, VEGF-R2 in patients with endometrial cancer (EC). MATERIAL/METHODS: The study group consisted of 118 patients with EC subjected to surgical treatment. Before the treatment we determined the serum levels of cytokines IL-8, and VEGF as well as VEGFR1 and VEGFR2 receptors. For comparison, the concentration of CA 125 was also measured. VEGFR1 and CA 125 were determined in the COBAS e601 system using Roche Diagnostics kits, while IL-8, VEGF and VEGFR2 were measured by ELISA assay using R&D Systems kits. RESULTS: The concentrations of IL-8, VEGF, VEGFR1 and CA 125 allowed to distinguish patients for the control group. The highest diagnostic sensitivity has been shown for the concentrations of VEGF (AUC = 0.904) and IL-8 (AUC = 0.818). Among all studied parameters only CA125 concentrations increased with the clinical stage; being significantly higher in patients in FIGO III-IV, than FIGO I-IB. In patients at the FIGO stage I-IB, complementary determinations of CA 125 and VEGF resulted in the largest increase of diagnostic sensitivity. Patients with metastases to the para-aortic lymph nodes had significantly higher levels of VEGF compared to subjects without such lesions. The concentrations of IL-8 were an independent prognostic factor in the assessment of overall survival in patients with type I endometrial cancer, while the concentrations of VEGFR2 in those with type II. CONCLUSIONS: In patients with endometrial cancer, the clinical usefulness of IL-8 and VEGFR2 measurements as the potential prognostic factors has been demonstrated. In type I, the concentrations of IL-8 determined before treatment can be helpful in predicting overall survival. In patients qualified to type II EC, the concentrations of VEGFR2 have the value of an independent prognostic factor for overall survival, this requires research on larger groups of patients. The increased levels of VEGF may be useful in the preoperative assessment of the status of para-aortic lymph nodes. Public Library of Science 2017-10-09 /pmc/articles/PMC5633267/ /pubmed/28991928 http://dx.doi.org/10.1371/journal.pone.0184576 Text en © 2017 Kotowicz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kotowicz, Beata
Fuksiewicz, Malgorzata
Jonska-Gmyrek, Joanna
Berezowska, Alicja
Radziszewski, Jakub
Bidzinski, Mariusz
Kowalska, Maria
Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title_full Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title_fullStr Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title_full_unstemmed Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title_short Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients
title_sort clinical significance of pretreatment serum levels of vegf and its receptors, il- 8, and their prognostic value in type i and ii endometrial cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633267/
https://www.ncbi.nlm.nih.gov/pubmed/28991928
http://dx.doi.org/10.1371/journal.pone.0184576
work_keys_str_mv AT kotowiczbeata clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT fuksiewiczmalgorzata clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT jonskagmyrekjoanna clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT berezowskaalicja clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT radziszewskijakub clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT bidzinskimariusz clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients
AT kowalskamaria clinicalsignificanceofpretreatmentserumlevelsofvegfanditsreceptorsil8andtheirprognosticvalueintypeiandiiendometrialcancerpatients